BMS-955176

From Food & Medicine Encyclopedia

Revision as of 00:49, 20 February 2025 by Prab (talk | contribs) (CSV import)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

BMS-955176‏‎ is an antiviral drug that was under development by Bristol-Myers Squibb for the treatment of HIV infection. It is a second-generation maturation inhibitor, a class of drugs that interfere with the final stage of the HIV life cycle.

History[edit]

BMS-955176‏‎ was developed as a follow-up to bevirimat, the first maturation inhibitor to reach clinical trials. Bevirimat showed promise in early trials, but its effectiveness was limited by naturally occurring variations in the HIV virus. BMS-955176‏‎ was designed to overcome these limitations and showed activity against a wider range of HIV variants in preclinical studies.

Mechanism of Action[edit]

As a maturation inhibitor, BMS-955176‏‎ interferes with the final step in the HIV life cycle, the conversion of the immature virus particle into a mature, infectious virus. It does this by binding to the Gag protein, a key structural protein of the virus, and preventing it from being cleaved by the viral protease enzyme. This leaves the virus in an immature state and unable to infect new cells.

Clinical Trials[edit]

BMS-955176‏‎ has been tested in Phase IIb clinical trials. The results showed that the drug was generally well tolerated and had a similar efficacy to other antiretroviral drugs when used in combination therapy. However, development of the drug was discontinued in 2016 for reasons that were not publicly disclosed.

See Also[edit]

BMS-955176[edit]

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.